Preferred Label : RBCs-Anti-PD1 Antibody Conjugate WTX212;
NCIt synonyms : RBCs Conjugated with Pembrolizumab WTX212; Erythro-Drug Conjugate WTX212; RBCs-Anti-PD-1 Antibody Conjugate WTX212; Erythrocyte-Anti-PD1 Antibody Conjugate WTX212;
NCIt definition : A preparation of autologous engineered red blood cells (RBCs) conjugated with pembrolizumab,
an antibody against the negative immunoregulatory human cell receptor programmed cell
death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory
and antineoplastic activities. Upon administration of the RBCs-anti-PD1 antibody conjugate
WTX212, the RBCs primarily and directly distribute to the spleen and vascular system.
The anti-PD1 antibodies target, bind to and inhibit PD-1, leading to the abrogation
of PD1-mediated downregulation of T-cell activation and proliferation. This restores
immune function, decreases programmed cell death-1 ligand 1 (PD-L1)-positive myeloid-derived
suppressor cells (MDSCs) and regulatory T-cells (Tregs) and activates a cytotoxic
T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1, a transmembrane
protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as
an immune checkpoint that negatively regulates T-cell activation and effector function
when activated by its ligands PD-L1 (cluster of differentiation 274; CD274) or 2 (PD-L2;
CD273); it plays an important role in tumor evasion from host immunity.;
Molecule name : WTX-212; WTX 212;
Origin ID : C201649;
concept_is_in_subset
